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The recent surge of research into new broadly neutralizing antibodies in HIV-1 infection has
recharged the ﬁeld of HIV-1 vaccinology. In this review we discuss the currently known
broadly neutralizing antibodies and focus on factors that may shape these antibodies in
natural infection.We further discuss the role of these antibodies in the clinical course of the
infection and consider immunological obstacles in inducing broadly neutralizing antibodies
with a vaccine.
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INTRODUCTION
Thirty years after the discovery of HIV, UNAIDS estimates 34
million people are living with HIV and nearly 30 million people
have died of AIDS-related causes since the ﬁrst case of AIDS was
reported on 5 June 1981 (www.unaids.org; Centers for Disease
Control, 1981). While the number of new infections is declin-
ing globally and access to anti-retroviral (ARV) therapy for low-
and middle-income countries has expanded to 6 million currently
on treatment, the number of new HIV infections is still high at
7000 each day. However, recent advances with varying efﬁcacy
have been made in the prevention of HIV infection, which include
adult male circumcision (Auvert et al., 2005; Bailey et al., 2007),
ARV-based vaginal microbicides (Abdool et al., 2010), and pre-
exposure prophylaxis (Grant et al., 2010). Moreover, the recent
HPTN 052 trial has shown that ARV treated HIV-infected indi-
viduals are 96% less likely to transmit HIV to their uninfected
partner (Cohen et al., 2011). However, ARV treatment would be a
costly and complicated solution to halt the pandemic as the num-
ber of people infected still far surpasses the number of people
treated and adherence to therapy is suboptimal. New preven-
tative strategies are absolutely necessary, as several of currently
known strategies pose challenges in implementation, not only
in resource poor countries. Vaccines are by far the best strat-
egy to prevent infection by all kinds of pathogens. For most
vaccines against viruses, antibodies are a correlate of protection
(Amanna et al., 2008; Plotkin, 2008).
Despite years of research, there is no vaccine that can estab-
lish protective immunity against HIV. The RV144 HIV vaccine
trial was, however, the ﬁrst to show some modest efﬁcacy
against acquisition of infection (Rerks-Ngarm et al., 2009). In
this trial protection against infection was associated with anti-
bodies directed against the second variable (V2) domain in the
envelope of HIV. For a higher level or even complete protec-
tion against HIV infection, the upfront presence of neutralizing
antibodies is considered to be most efﬁcacious. To cover the
huge variability of HIV-1, vaccine elicited neutralizing antibodies
would need to be broadly reactive. However, broadly neutral-
izing antibodies were considered rare and moreover, attempts
to design an immunogen capable of eliciting broadly neutraliz-
ing antibodies have failed so far. However, recent studies in the
ﬁeld have shown that broadly neutralizing antibodies may be
more prevalent in HIV-1 infection than previously considered
and these antibodies seem to have varying epitope speciﬁcities
that could allow for multidirectional vaccine design. Here we
review the role of broadly neutralizing antibodies in protection
from HIV infection and HIV disease progression. In addition,
we provide an overview of the speciﬁcities of the broadly neu-
tralizing antibodies that are known to date and how this could
translate in the optimal immunogen. Finally we discuss the con-
ditions that may need to be fulﬁlled to elicit a protective humoral
immune response.
NEUTRALIZING ANTIBODIES TO HIV-1
The ﬁrst detectable antibodies directed against the HIV-1 enve-
lope appear around 12 days after infection. These antibodies
are non-neutralizing, directed against the gp41 region, and
mainly forming immune complexes (Tomaras and Haynes, 2009;
Figure 1). Approximately 2 weeks later, antibodies are formed
against the immunodominant gp120 region and these are also
non-neutralizing. Neutralizing antibodies appear for the ﬁrst
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FIGURE 1 | Sequentially elicited antibodies to HIV-1 envelope over the course of the infection.
time around 3 months post-seroconversion. These antibodies are
mostly strain-speciﬁc and cannot neutralize heterologous viruses.
Autologous neutralizing antibodies can rapidly select for escape
variants of HIV-1 and do not seem to have a protective effect
against progression to AIDS (Richman et al., 2003; Wei et al., 2003;
Bunnik et al., 2008; Mahalanabis et al., 2009; van Gils et al., 2010).
HIV-1 envelope is one of themost extensively glycosylated proteins
found in nature (Myers and Lenroot, 1992). The glycans on the
protein shield the conserved envelope domains from recognition
by neutralizing antibodies. Also, as the glycans originate from the
host cellmachinery, they are usually not recognizedby the immune
system as foreign. Removal of glycosylation sites within or around
the variable domains made the virus more susceptible to antibody
neutralization (Reitter et al., 1998; Binley et al., 2010). The virus
can escape neutralizing antibodies through additional potentialN-
linked glycosylation sites (PNGS) in the viral envelope or through
changed positions of PNGS. The envelope also contains hyper-
variable regions that can change in length or amino acid sequence.
HIV-1 variants with these changes can be rapidly selected under
neutralizing antibody pressure if these changes coincide with an
increased resistance to circulating neutralizing antibodies. Broadly
neutralizing antibodies are directed against conserved regions of
the virus and therefore capable of neutralizing a large variety of
viruses fromdifferent subtypes. As these broadly neutralizing anti-
bodies generally neutralize the majority of recently transmitted
HIV-1 variants (Binley et al., 2004; Bunnik et al., 2010; Euler et al.,
2011), irrespective of number of PNGS and variable loop length,
a vaccine should be able to elicit this type of antibodies.
THE FIRST BROADLY NEUTRALIZING ANTIBODIES
Prior to 2009, the presence of broadly neutralizing antibodies in
HIV-1-infected individuals was considered rare. At that time, only
four monoclonal antibodies (MAbs) had been isolated that could
potently neutralize amajority of primaryHIV-1 strains (Figure 2).
MAb b12 was the ﬁrst broadly neutralizing antibody and obtained
from the bone marrow of an asymptomatic HIV-infected man
(Burton et al., 1994; Kessler et al., 1997; Saphire et al., 2001). More
speciﬁcally, it was isolated from a phage display library in which
heavy and light chains are recombined in vitro to Fab fragments,
and subsequently modiﬁed into complete IgG molecules. This
may imply that the b12 antibody had not existed in vivo in the
patient but only emerged due to in vitro recombination of heavy
and light chains. The epitope on HIV-1 that is recognized by b12
lies in the CD4-binding site of the envelope. Crystal structures
have revealed that the contact surfaces of b12 and CD4 on the
viral envelope are considerably overlapping (Zhou et al., 2007),
which could explain the neutralizing activity. However, overlap
with the CD4-binding site alone is not sufﬁcient for neutraliza-
tion as the footprint for b12 on the CD4-binding site in Env
overlaps with the footprints of antibodies b3 and b6 which are
highly related to b12 but non-neutralizing. Antibodies b3 and
b6 bind beyond the neutralizing face, into the non-neutralizing
face and are unlike b12, not able to bind to trimeric Env
(Pantophlet et al., 2003).
At the time, the only other broadly neutralizing antibody that
was directed against gp120 was 2G12. This antibody has a very
unusual dimer conformation and is directed against mannose
structures on gp120,which results frompost-transcriptionalmod-
iﬁcations by the host cell (Trkola et al., 1996; Sanders et al., 2002;
Scanlan et al., 2002; Doores et al., 2010). Two of the other ﬁrst
identiﬁed broadly neutralizing MAbs, 4E10 and 2F5, were not
directed against gp120 but instead against the membrane proxi-
mal region (MPER) in gp41 on the viral spike (Ofek et al., 2004;
Cardoso et al., 2005; Zwick et al., 2005; Pejchal et al., 2009). These
antibodies can only bind to their epitope in the context of the
lipid bilayer of the membrane (Alam et al., 2007, 2009). Overall
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FIGURE 2 | Epitope specificity of known broadly neutralizing
antibodies to HIV-1 envelope. Adapted from White et al. (2010).
mAbs b12, 2G12, 2F5, and 4E10 neutralize approximately 35, 21,
43, and 56% of viral variants, respectively (Binley et al., 2004).
Interestingly, there was an inverse correlation between breadth
and potency of these antibodies, with b12 being potent, but not as
broad, while 2F5 and 4E10 neutralized the majority of strains but
with limited potency. Even among HIV-1 variants that were iso-
lated from recently infected individuals, a relatively large number
of neutralization resistant viruses were found (Quakkelaar et al.,
2007; Euler et al., 2011) already suggesting that vaccine elicited
antibodies would need to be better than these four antibodies to be
efﬁcacious. This and the unusual characteristics and rarity of b12,
2G12, 4E10, and 2F5 antibodies raised the quest to screen large
cohorts for cross-reactive neutralizing activity (CrNA), in order
to ﬁnd broadly neutralizing antibodies with new epitope speciﬁci-
ties that could be used for the design of immunogens capable of
eliciting more potent CrNA in a vaccine setting.
THE SEARCH FOR HIV-1-SPECIFIC CrNA
Large scale screening for CrNA in patient sera has intensiﬁed over
the past few years in several cohorts across the world, that har-
bor individuals infected with different HIV-1 subtypes. Screening
methods vary between different cohorts, especially with regards to
the in vitro neutralization assays and the virus panels used, which
could accurately deﬁne CrNA. Most widely used are a multiple-
round peripheral blood mononuclear cell (PMBC)-based assay
that requires primary virus isolates and a single-round infection
assay using a reporter cell line, such as TZM-bl, that requires
pseudoviruses produced by 293T cells. The neutralization sensi-
tivity of viruses does vary between these two assays (Polonis et al.,
2008, 2009; Fenyo et al., 2009; Rusert et al., 2009). However, there
is a positive correlation between the PBMC- and TZM-bl-based
assay in the identiﬁcation of individuals with CrNA (van Gils et al.,
2009). CrNA is deﬁned as the ability of patient sera to neutralize
the majority of viruses from different subtypes, although the exact
cut off for CrNA varies per study. This may also explain, as least in
part, the variation in prevalence of CrNA between cohorts, which
varies from 10 to 33% (Beirnaert et al., 2000; Binley et al., 2008;
Sather et al., 2009; Simek et al., 2009; van Gils et al., 2009; Doria-
Rose et al., 2010; Euler et al., 2010; Medina-Ramirez et al., 2011;
Mikell et al., 2011). In one of the largest studies, in which ∼1800
HIV-1-infected people from Australia, Rwanda, Uganda, the
United Kingdom, and Zambia were screened for CrNA on various
virus panels, a mathematical algorithm was devised to reduce to
amount of viruses that could predict the presence of CrNA (Simek
et al., 2009). This large study also for the ﬁrst time described the
phenomenon of “elite neutralizers” (Simek et al., 2009) who in
their serum have an average geometric mean IC50 titer of over
500, generally representing the top 1% of individuals with CrNA
in serum within a cohort. This phenotype is independent of the
clinical status of a person. CrNA in serum is not particular to indi-
viduals with an HIV-1 infection, as three recent studies showed
that individuals with an HIV-2 infection have even more potent
CrNA than individuals infected with HIV-1 (de Silva et al., 2012;
Kong et al., 2012; Ozkaya et al., 2012). Identiﬁcation of individuals
with potent CrNA allows for the discovery of more broadly neu-
tralizing antibodies with new epitope speciﬁcities based on which
vaccine immunogens can be designed (Stamatatos et al., 2009).
CrNA IN THE CLINICAL COURSE OF HIV-1 INFECTION
Broadly neutralizing antibodies are directed against conserved
regions of the virus which may explain why these antibodies
can neutralize a vast array of different HIV-1 strains from dif-
ferent subtypes. Based on this, it was plausible to think that
broadly neutralizing antibodies would be capable of neutraliz-
ing the autologous virus strain in vivo, thereby reducing viral load
and halting disease progression. As the ﬁrst broadly neutralizing
monoclonal antibody, b12, was isolated from an asymptomatic
seropositive individual (Burton et al., 1991), it was thought that
these antibodies were indeed able to protect from disease pro-
gression in vivo. However, after several screenings on long-term
non-progressors (van Gils et al., 2009; Doria-Rose et al., 2010),
elite controllers (Pereyra et al., 2008) and progressors (van Gils
et al., 2009; Doria-Rose et al., 2010), there was no evidence that
long-term non-progressors had better CrNA as compared to
progressors. Indeed, recent screenings of entire cohorts of HIV-
1-infected individuals, both men who have sex with men (MSM)
with subtype B infections as well as heterosexually infectedwomen
with HIV-1 subtype C, did not show an association between the
presence of CrNA and a prolonged asymptomatic phase in the
course of HIV-1 infection (Piantadosi et al., 2009; van Gils et al.,
2009; Euler et al., 2010; Gray et al., 2012). In a study with both
long-term non-progressors and progressors, in which the preva-
lence of CrNA in serum was similar in both groups, neutralizing
activity against autologous HIV-1 variants faded over time due to
viral escape (Figure 1), explaining at least in part the absent effect
of potent CrNA on the clinical course of infection (van Gils et al.,
2010). Interestingly, CrNA against heterologous virus variants was
preserved over the course of infection, despite escape of autol-
ogous virus. With the knowledge that CrNA generally takes 2–4
years to develop (Figure 1; Mikell et al., 2011; Euler et al., 2012;
Gray et al., 2012) one could argue that the neutralizing humoral
immune response simply comes too late to have an impact on dis-
ease course. Indeed, prior to the development of these antibodies
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the immune systemmayhave been irreversibly damaged (Levesque
et al., 2009), although obviously the ability of the patient to still
develop CrNA argues against this. Even an elite neutralizer with
potent CrNA from month 9 post-seroconversion onwards, that
even further increased in breadth and potency until 3 years post-
seroconversion, progressed to full blown AIDS within 7.5 years
post-seroconversion (Euler et al., 2012). Interestingly, in this indi-
vidual in particular, but also in other individuals with CrNA, an
early diversiﬁcation of the viral quasispecies was observed, which
was not observed in individuals who did not develop CrNA. This
may imply that CrNAprovides extra immune pressure on the virus
to escape and diversify as compared to autologous neutralizing
activity that lacks cross-reactivity.
PROTECTION IN MONKEYS BY BROADLY NEUTRALIZING
ANTIBODIES
Despite the lack of protection against disease progression in indi-
viduals who naturally made broadly neutralizing antibodies in
vivo, it cannot be excluded that these antibodies can protect
against acquisition of infection when present at the time HIV-1 is
encountered. Several studies in non-human primates have shown
that passive immunization can confer protection against SIV or
SIV/HIV hybrid virus (SHIV) infection in macaque models (Mas-
cola et al., 1999, 2000; Parren et al., 2001;Veazey et al., 2003; Hessell
et al., 2009a). Even at a relatively low antibody dose, b12 and 2G12
conferred protection in a repeat challenge model (Hessell et al.,
2009a,b). Passive immunizations with antibodies b12, 2G12, and
2F5 also protected newborn macaques from oral SHIV challenge
(Baba et al., 2000; Hofmann-Lehmann et al., 2001). Furthermore,
vector mediated delivery of genes expressing broadly neutraliz-
ing antibodies in a humanized mouse model conferred protection
against subsequent high dose viral challenges (Johnson et al., 2009;
Balazs et al., 2012). This suggests that pre-existing humoral immu-
nity may be able to prevent HIV-1 infection. Indeed, in a recent
study, macaques that were vaccinated with MVA and/or adeno
viral vectors expressing SIV Gag, Pol, and Env, partial pro-
tection against acquisition of the highly neutralization resistant
SIVMAC251 challenge correlated with the presence of Env-speciﬁc
binding and tier 1 neutralizing antibody titers prior to vaccina-
tion, speciﬁcally with an anti-V2 antibody response in the animals
(Barouch et al., 2012).
NEXT GENERATION BROADLY NEUTRALIZING ANTIBODIES
The screening for patients with CrNA in serum has intensiﬁed
and so have the methods to isolate the broadly neutralizing anti-
bodies from these patients. Several high-throughput techniques
have been implemented (as reviewed by Moir et al., 2011) which
has resulted in new antibodies that can neutralize the majority of
HIV-1 strains tested, with a potency of up to four orders of mag-
nitude to the previously identiﬁed broadly neutralizing antibodies
(Figure 2).
EPITOPE SPECIFICITIES OF BROADLY NEUTRALIZING ANTIBODIES
CD4-binding site
The host CD4 molecule is the major receptor for HIV-1. Attach-
ment of Env gp120 to CD4 on the target cell initiates infection.
Therefore, antibodies directed against the CD4-binding site on
the gp120 envelope molecule are crucial to prevent binding of the
virus to its host cell. In one approach, B cells that produced anti-
bodies directed to the CD4-binding site of HIV-1 were isolated
with a probe with a resurfaced stabilized core 3 (RSC3) in which
all areas except the CD4-binding site of the virus were altered or
masked, making those unfavorable for recognition (Zhou et al.,
2010). With this method the MAbs, VRC01, VRC02, VRC03,
and VRC-PG04, were cloned which bind speciﬁcally to the CD4-
binding site, mimicking the binding between HIV-1 and the CD4
receptor (Wu et al., 2010, 2011; Zhou et al., 2010) with several
overlapping binding sites. In a similar approach by Scheid et al.
(2011), several highly active agonistic CD4-binding site directed
antibodies (HAADs) were isolated from four unrelated elite neu-
tralizers with a method that was described earlier (Scheid et al.,
2009b). In this approach, single B cells were sorted with a probe
that binds to a HIV gp120 core glycoprotein which was stabilized
in the CD4-bound conformation and lacking the V1, V2, and V3
region (2CC core). Subsequently the corresponding heavy and
light chains from these sorted B cells were cloned and expressed
in cells that secreted the antibodies. Unlike the RSC3, the 2CC
also binds to antibodies speciﬁc for the CD4-induced co-receptor
binding site. To amplify the immunoglobulin gene, primers were
selected further upstream from the highly variable complemen-
tary determining region 3 (CDR3) to circumvent the problem of
the unusually high somatic mutations of the broadly neutraliz-
ing antibodies, as discussed below. With this method, 576 new
antibodies were cloned, of which some were on par or even more
potent than VRC01, including the antibodies 3BNC117, 3BNC60,
and NIH45–46. These antibodies strongly resemble VRC01 both
in crystal structure and in sequence convergence, including 10 of
the contact residues between VRC01 and the HIV spike. In an
attempt to increase the potency and breadth of these antibod-
ies, based on structures-based design, Diskin et al. (2011) made
a single substitution in the CDR2 of the heavy chain of NIH45–
46 to create NIH45–46G54W,which increased the contact with the
gp120 bridging sheet in turn improving the potency by an order
of magnitude.
Quaternary antibodies against the variable loops in the viral
envelope
In another large scale study, the approach of non-speciﬁc high-
throughput memory B cell culture was taken (Walker et al., 2009,
2011). In this system activated B cells are cultured at near clonal
density and the secreted antibodies are subsequently tested for
neutralizing activity against a panel of HIV-1 variants. The corre-
sponding heavy and light chain from B cells that secreted broadly
neutralizing antibodies could then be reconstituted. With this
technique, antibodies against novel epitopes of the viruswere iden-
tiﬁed. Two such antibodies are PG9 and PG16, which are directed
against an epitope that is preferentially expressed on the trimeric
HIV Env protein across conserved regions of the variable loops
of gp120 (Walker et al., 2009; Pancera et al., 2010). Since then, the
antibodies CH01–04 (Bonsignori et al., 2011) and PGT141–145
(Walker et al., 2011) have been identiﬁed that target this same
region. The recent crystal structure of gp120 V1V2 with PG9
revealed that this antibody as well as CH04 and PGT145 share
a common mode of glycan penetration by extended anionic loops
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(McLellan et al., 2011). Although the epitopes of these antibodies
are present in the monomeric structure, they are sensitive to the
orientation of the viral spike and bind with a higher afﬁnity to the
trimeric form of gp120.
Glycan dependant antibodies
The non-speciﬁc high-throughput memory B cell culture system
was performed with the B cells of four elite neutralizers, which
resulted in the isolation of a new class of broadly neutralizing
antibodies, termed the PGT series. These antibodies are directed
against mannose structures and appear to be 10- to 100-fold more
potent than other antibodies (Walker et al., 2011). Crystal struc-
tures of fab PGT128 together with a fully glycosylated gp120 outer
domain showed that the antibody penetrates the glycan shield and
recognizes two conserved glycans on positions N301 and N332,
as well as a short β-strand segment of the V3 loop (Pejchal et al.,
2011). The glycosylation sites which often shield the conserved
sites of envelope against neutralizing antibodies, in this case render
the virus more sensitive to neutralization.
EPITOPE MAPPING
In order to ﬁnd even more potentially conserved regions within
the virus envelope, the undertaking of extensive epitope mapping
of broadly neutralizing activity in sera of patients with CrNA has
revealed various antibody speciﬁcities. There appears to be a dif-
ference in the number of antibody speciﬁcities between individuals
with CrNA that is not so potent, and the so-called elite neutraliz-
ers (Simek et al., 2009). Previous studies on sera from individuals
with CrNA with lower potency than observed in elite neutraliz-
ers showed that multiple epitope speciﬁcities exist within each
infected individual (van Gils et al., in preparation; Dhillon et al.,
2007; Li et al., 2007; Binley et al., 2008; Scheid et al., 2009a; Sather
and Stamatatos, 2010; Tomaras et al., 2011). Conversely, CrNA in
elite neutralizers was restricted to one or two epitope speciﬁcities
per individual (Walker et al., 2010). Although the speciﬁcity was
restricted within an individual, epitope speciﬁcity varied between
individuals with elite neutralizing activity. Major antibody targets
were associated with conserved regions of the V1, V2, and V3
loops as deﬁned by the broadly neutralizing antibodies PG9 and
PG16, as well as with an epitope overlapping the CD4-binding site.
Identifying individuals with new epitope speciﬁcities could nar-
row the number of individuals from whom to isolate new broadly
neutralizing antibodies.
FACTORS INFLUENCING BROADLY NEUTRALIZING
ANTIBODY FORMATION
A better understanding of how CrNA develops during the natu-
ral course of infection in some individuals will give valuable clues
for vaccine design. CrNA is positively correlated with viral load,
especially during the primary stage of infection (Piantadosi et al.,
2009; Sather et al., 2009; van Gils et al., 2009; Doria-Rose et al.,
2010; Mikell et al., 2011; Gray et al., 2012). This most likely impli-
cates that sufﬁcient antigen is required to stimulate theneutralizing
humoral immune response. Surprisingly, CrNA is also associated
with lower CD4 T cell counts early in infection (Euler et al., 2010;
Gray et al., 2012). One could argue that these lowCD4T cell counts
are probably just a consequence of the high viral load. However,
the association was even observed for pre-seroconversion CD4
T cell counts (Euler et al., 2010). Furthermore,MSM showed more
potent CrNA than injecting drug users (IDU; Euler et al., in prepa-
ration) which could be attributed to the presence of women in the
cohort. Women had higher CD4 T cell counts at setpoint, which
was the only independent predictor for the presence of CrNA in
the Amsterdam Cohort studies.
As intact CD4 helper cells are necessary for class switching and
multiple rounds of somatic hypermutation, this seems counter-
intuitive. Interestingly, in a lymphocytic choriomeningitis virus
(LCMV) mouse model, lower CD4 T cell counts resulted in less
HIV-1-induced polyclonal B cell activation, which in turn boosted
virus-speciﬁc antibodies (Recher et al., 2004; Lang et al., 2007).
Moreover, αβ T cell deﬁcient mice still develop normal germinal
centers and class-switched antibodies, in which case γδ T cells
might be able to provide B cell “help” (Wen et al., 1996; Mbow
et al., 2001; Brandes et al., 2003). It is tempting to speculate that
only B cells with highest afﬁnity will get sufﬁcient help under con-
ditions that CD4 cell counts are limited, thus contributing to the
outgrowth of B cells with even higher afﬁnity for their epitope.
Although CrNA was associated with overall lower CD4 T cell
levels prior to infection and during acute infection, there was a
positive association with the fraction of CD4 T cells expressing
high levels of PD-1 (Mikell et al., 2011). PD-1 is expressed on
follicular T helper cells and plays a crucial role in the formation of
germinal centers and the proliferation and survival of circulating
plasma cells (Good-Jacobson et al., 2010).
In a recent genome wide association study (GWAS) on the
development of CrNA, we have found several single nucleotide
polymorphisms (SNPs) in the gene region of MHC class I chain-
related protein A (MICA) on chromosome 6 that were associated
with the development of CrNAat 3 years post-serconversion (Euler
et al., submitted for publication). The association of these SNPs
with CrNA was strong but did not reach genome wide signiﬁ-
cance after correction for multiple testing and conﬁrmation of
this ﬁnding is required. Interestingly, previous studies have shown
strong associations between SNPs on chromosome 6 and viral
load set point (Fellay et al., 2007; Dalmasso et al., 2008; Pelak et al.,
2010) which as mentioned above by itself has been associated with
CrNA in several studies (Piantadosi et al., 2009; Sather et al., 2009;
van Gils et al., 2009; Doria-Rose et al., 2010; Mikell et al., 2011;
Gray et al., 2012). However, the association between MICA and
CrNA was only partially decreased after correction for viral load
as a covariate, indicating that other yet unknown mechanisms
independent of viral load could play a role in the development
of CrNA.
Other covariates such as HLA class II alleles, risk group, history
of using ARVs, race, ethnicity, gender, and age were not asso-
ciated with the development of CrNA (Doria-Rose et al., 2010;
Euler et al., submitted for publication).
Obviously, characteristics of the HIV-1 variant that is transmit-
ted can also have an impact on the induction of CrNA. In order
to ﬁnd viral genetic signatures associated with CrNA,Gnanakaran
et al. (2010) screened sera from 69 individuals for CrNA and sub-
sequently clustered them in a high and a low neutralizing potency
group. Six signature positions in the Env sequences of their HIV-1
variants were associated with high or low neutralizing potency in
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serum. Five of these were in the CD4-induced co-receptor binding
site of gp120. A similar approach in a subtype C-infected cohort
showed that shorter V1–V4 regions from autologous viruses cor-
responded with higher neutralization against a heterologous viral
panel (Rademeyer et al., 2007). In this study, Envs were isolated at
the same time point at which CrNA was detected. At that point,
HIV-1 may have already escaped from autologous neutralization
(van Gils et al., 2010; Euler et al., 2012) and one could therefore
argue that these Env sequences have signals for escape from CrNA,
rather than signals that are speciﬁc for the induction of CrNA.
HIV-1 variants isolated during the primary stage of infection with
proven sensitivity to autologous serum with CrNA might be more
relevant for the identiﬁcation of signatures between individuals
with and without CrNA. A more open viral envelope conﬁgu-
ration might better expose certain conserved epitopes that can
induce the formation of these antibodies. In a recent study we have
revealed an association between CrNA in serum and the presence,
in the ﬁrst year of infection, of HIV-1 variants with envelopes that
had a shorter V1 region and a lower NXS/NXT ratio, the latter
indicating fewer PNGS (van den Kerkhof et al., in preparation).
These viruses were still sensitive to autologous serum neutraliza-
tion and may have been the drivers for eliciting CrNA in these
patients.
VACCINE ELICITED CrNA: IMMUNOLOGICAL OBSTACLES
The known broadly neutralizing antibodies have unique charac-
teristics, which also complicates the induction of these antibodies.
A majority of broadly neutralizing antibodies have a long CDR3
in their immunoglobulin heavy chains. Two such antibodies, PG9
and PG16, have an exceptionally long CDR3, which forms a type
of “hammerhead” with which it interacts with HIV-1 Env. Inter-
estingly, it appears that B cells with long CDR3 regions undergo
negative selection at the naïve B cells stage (Shiokawa et al., 1999;
Meffre et al., 2001). Polyreactive and self-reactive B cells are also
negatively selected at the early B cell stages, yet in HIV-1 infection,
several broadly neutralizing antibodies are polyreactive (Haynes
et al., 2005), and up to 70% of memory B cells speciﬁc for HIV-1
Env from individuals with CrNA are thought to be polyreactive
(Mouquet et al., 2010), deﬁned by their ability to bind to mul-
tiple and distinct antigens on self-antigens and other non-viral
antigens. It is thought that the low density of viral spikes on the
membrane of HIV-1 causes antibodies to bind bivalently to both
the gp160 trimer and non-HIV antigens resulting in higher afﬁn-
ity, but in turn also more polyreactivity (Klein and Bjorkman,
2010). In a study to test if afﬁnity could enhance the neutralizing
capacity of bivalent antibodies, bi-speciﬁc anti-HIV-1 antibodies
were engineered that bind gp120 with one arm and gp41 with the
other. These bi-speciﬁc antibodies were better neutralizers than
their independent parental mono-speciﬁc antibodies (Mouquet
et al., 2012). Mouquet et al. (2010) hypothesized that during the
primary immune response to HIV-1, polyreactive B cells are posi-
tively selected due to their strong afﬁnity, which is based on their
bivalent binding, which is known to correlate with virus neutral-
ization. It has been suggested that anti-gp41 antibodies formed
during the acute infection are polyreactive due to gp41-specﬁcic
B cell stimulation of non-HIV-1 antigens prior to infection
(Liao et al., 2011).
However, polyreactivity is noprerequisite for antibodies to neu-
tralize HIV, as b12, 2G12, andVRC01 have very little polyreactivity
(Haynes et al., 2005). Also the new broadly neutralizing PGT anti-
bodies have very little polyreactivity, despite the fact that their
epitope is from host origin (Walker et al., 2011).
Another unique characteristic of broadly neutralizing antibod-
ies is the high degree of somatic mutations within the CDR3
region as compared to antibodies in other infections which typi-
cally accumulate only 5–15% changes in this region during afﬁnity
maturation (Wrammert et al., 2011). The degree of somatic muta-
tions of the known broadly neutralizing antibodies ranges from
6% for 4E10 (McElrath and Haynes, 2010) to 19% for PG9 and
PG16 (Walker et al., 2009) and to up to 32% for some of the
CD4-binding site directed antibodies (Wu et al., 2010). Thus,
the mutational pathways for creating such neutralizing antibodies
could be more complex than those from other diseases (Dimitrov,
2010). In vitro reverted unmutated ancestor antibodies from HIV-
1-speciﬁc broadly neutralizing antibodies have shown little or no
reactivity with the epitopes of their progeny broadly neutralizing
antibodies (Xiao et al., 2009; Mouquet et al., 2010; Pancera et al.,
2010; Zhou et al., 2010; Bonsignori et al., 2011). This indicates
that broadly neutralizing antibodies in general may need multiple
rounds of somatic mutation and afﬁnity maturation and that the
currently known recombinant envelope glycoproteins are insuf-
ﬁcient in promoting this process to achieve the desired mature
antibodies from precursor naïve B cells. However, when Env was
partially deglycosylated, the reverted unmutated ancestors of 2F5
and 4E10, could bind to these Envs, but not to the fully glyco-
sylated Env (Ma et al., 2011). This suggests that germline B cell
receptors have the capacity to bind to the relevant epitopes, but
that this binding might be impeded or even prevented by glycan
interference. Additionally, germline predecessors of broadly neu-
tralizing antibodies have shown to be different between rhesus
macaques and humans (Yuan et al., 2011) which might explain
the limited success in the generation of these antibodies in ani-
mal models. Identifying antibodies that are intermediates in the
pathways to maturation, but not yet broadly neutralizing, could
help design conceptually novel vaccine immunogens (Dimitrov,
2010) as immunogens that can induce these intermediate anti-
bodies could guide the immune system to mature in the direction
of highly mutated broadly neutralizing antibodies.
Current strategies to unravel the pathway of afﬁnity matura-
tion that leads to the formation of broadly neutralizing antibodies
includes 454 pyrosequencing of B cells of HIV-1 individuals
to identify their antibody repertoire or antibodyome (Dimitrov,
2010; Bonsignori et al., 2011; Wu et al., 2011; Zhu et al., 2011). In
the study by Wu et al. (2011) the authors identiﬁed new VRC01-
like antibodies by means of sequence data obtained from bulk
PMBC, with high divergence from the inferred germline genes
and sequence similarity to VRC01. They observed high structural
convergence to the epitope-binding region as well as functional
complementation between the heavy and light chains of all these
antibodies, suggesting that these antibodies could mature in the
same way and therefore could predict the maturation of these
antibodies. However, the question remains if such maturation
pathways can be induced in vivo. In one recent study, in order
to program the B cell response, the natural evolution within
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HIV-infected individuals was mimicked in an animal model by
sequential immunization with different Env proteins. Compared
to animals that received a cocktail of Envs and only one clonal Env,
the sequential immunizations resulted in the highest heterologous
neutralization titers (Malherbe et al., 2011), suggesting that the
immune response can be focused towards a broader neutralizing
response. These results can imply that vaccination against HIV-
1 may need multiple long-term boosting with different antigens.
Indeed, an extra late stage boost in the RV144 trial could have
potentially improved the efﬁcacy in that study.
NEUTRALIZATION SENSITIVITY OF HIV-1 OVER THE
COURSE OF THE EPIDEMIC: SETTING THE BAR FOR
VACCINE DEVELOPMENT
Recently, we have shown that HIV-1 has become more resis-
tant to antibody neutralization over the course of the epidemic
(Bunnik et al., 2010). This effect was most notable to the CD4-
binding site directed antibodies b12 and VRC01 (Bunnik et al.,
2010; Euler et al., 2011). This increased resistance to humoral
immunity was associated with an extended and more heavily
potentially glycosylated V1 loop (Bunnik et al., 2010). Moreover,
the exchange of the V1V2 region from viruses isolated from indi-
viduals who seroconverted in the beginning of the epidemic with
the V1V2 regions from HIV-1 variants from contemporary sero-
converters, rendered the viruses more sensitive to neutralization
(van Gils et al., 2011). This implicates that the V1V2 loops shield
vulnerable epitopes, especially epitopes in the CD4-binding site,
from neutralizing antibodies.
Despite the increased neutralization resistance, currently circu-
lating HIV-1 strains are sensitive to neutralization by multiple of
the newly identiﬁed broadly neutralizing antibodies at low con-
centrations, in particular to Mabs PG9, PG16, VRC01 as well
as PGT121 and the HAADS 3BNC117, 3BNC60, and NIH45–46
(Euler et al., 2011; Euler et al., unpublished data). In the face of a
changing HIV-1 landscape over the course of 20 years, potent anti-
bodies with exceeding neutralizing breadth are required to target
multiple sites of the viral envelope in order to achieve sterilizing
immunity. With the newly identiﬁed antibodies against mannose
structures as well as new antibodies against the CD4-binding site
with an up to 10-fold increase in neutralization potency compared
to PG9, PG16, andVRC01 (Walker et al., 2011), contemporary cir-
culating HIV-1 strains should be neutralized by at least one of
the known broadly neutralizing antibodies. A vaccine that can
elicit these speciﬁcities would therefore likely be efﬁcacious even
against currently circulating, more neutralization resistant HIV-1
variants.
CONCLUSION
Many challenges remain in the development of an immunogen
that is capable of eliciting broadly neutralizing antibodies. Besides
the structural constraints on the immunogen, there are immuno-
logical barriers that need to be tackled, including the long afﬁnity
maturation that B cells seem to require before they can produce
broadly neutralizing antibodies, and the risk of eliciting antibod-
ies that have potential self-reactivity. If polyreactivity is a key
feature of broadly neutralizing antibodies, then the chances of
eliciting them with an envelope-based immunogen that is pre-
sented in the absence of a membrane context may be complicated
or even impossible. The identiﬁcation of even more broad and
potently neutralizing antibodies against not previously identiﬁed
epitopes will hopefully bring us ever more closer to the design
of an immunogen that can overcome these challenges. Most
circulating HIV strains are sensitive to the majority of broadly
neutralizing antibodies known to date in vitro. However, in vivo,
naturally developed broadly neutralizing antibodies have no effect
on disease progression as the virus easily escapes. Therefore, an
effectively neutralizing humoral immune response needs to be in
place prior to encountering HIV in order to prevent infection. As
soon as infection is established, the humoral immune response is
not likely to play a role in controlling viral replication.
An HIV vaccine is not available but huge progress has been
made in understanding what is required to neutralize HIV-1 and
how this type of immunity may be elicited. Understanding the
problem may pave the way to its solution.
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